$66B annually in weight loss injections spark pharma battle
The weight loss drug market, which was valued at $66 billion in a single year, has undergone a significant transformation, becoming a highly profitable investment opportunity with the entry of major companies such as Novo Nordisk and Eli Lilly. These companies now hold leading positions with market valuations exceeding one trillion dollars and over $570 billion, respectively. Current medications focus on reducing weight by up to 20% without surgical intervention, and results indicate that discontinuing them can lead to regaining about two-thirds of the lost weight within a year. This suggests the need for continuous, lifelong use to maintain results, guaranteeing a steady stream of revenue for the companies. As patent protections expire, drug prices are expected to decrease considerably, but challenges related to access and manufacturing, especially in developing countries, remain. While obesity is regarded as a chronic disease, companies continue to bet on long-term demand, raising questions about how long the market will remain a temporary solution rather than an ultimate cure.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading